Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been assigned a consensus recommendation of “Hold” from the six analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $5.00.

A number of research firms recently issued reports on ZNTL. Morgan Stanley dropped their target price on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 12th. Wedbush reissued a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 target price on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. Finally, Wall Street Zen upgraded Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 16th.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, insider Vincent Vultaggio sold 29,951 shares of the firm’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $2.43, for a total value of $72,780.93. Following the transaction, the insider directly owned 156,779 shares of the company’s stock, valued at approximately $380,972.97. This trade represents a 16.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $1.33, for a total transaction of $9,975,000.00. Following the transaction, the insider owned 6,459,973 shares of the company’s stock, valued at $8,591,764.09. This represents a 53.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 7,546,617 shares of company stock worth $10,088,417 in the last ninety days. Corporate insiders own 1.90% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Sivia Capital Partners LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter worth approximately $27,000. Catalyst Funds Management Pty Ltd purchased a new stake in Zentalis Pharmaceuticals in the 2nd quarter valued at $31,000. Voleon Capital Management LP bought a new position in Zentalis Pharmaceuticals during the 3rd quarter valued at $41,000. SG Americas Securities LLC boosted its holdings in Zentalis Pharmaceuticals by 35.3% during the 3rd quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock worth $48,000 after acquiring an additional 8,236 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter worth $37,000.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL opened at $2.39 on Friday. The stock has a market capitalization of $172.68 million, a P/E ratio of -1.15 and a beta of 1.73. The business has a 50 day simple moving average of $2.39 and a 200 day simple moving average of $1.82. Zentalis Pharmaceuticals has a one year low of $1.01 and a one year high of $3.95.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.